Cemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 Antibody
Cancer
A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE
Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.
-
Phase 1 Trials
REGN1979 CD20/CD3 Antibody
REGN1979
CD20 X CD3 AntibodyCancerCEMIPLIMAB + REGN1979
CEMIPLIMAB + REGN1979
PD-1 Antibody + CD20 X CD3 AntibodyCancerREGN3767*
REGN3767*
LAG-3 AntibodyCancerCEMIPLIMAB + REGN3767
CEMIPLIMAB + REGN3767*
PD-1 Antibody + LAG-3 AntibodyCancerREGN4018*
REGN4018*
MUC16 X CD3 AntibodyCancerCEMIPLIMAB + REGN4018*
CEMIPLIMAB + REGN4018*
PD-1 Antibody + MUC16 X CD3 AntibodyCancerREGN4659*
REGN4659*
CTLA4 AntibodyCancerREGN1908-1909
REGN1908-1909
Fel d 1 AntibodyCat allergyREGN-EB3 (REGN3470-3471-3479)
REGN-EB3 (REGN3470-3471-3479)
Ebola Virus AntibodyEbola virus infectionREGN3048-3051
REGN3048-3051
Middle Eastern Respiratory Coronavirus AntibodyMERS-CoV infectionPOZELIMAB
POZELIMAB
C5 AntibodyParoxysmal nocturnal hemoglobinuriaGARETOSMAB + TREVOGRUMAB
GARETOSMAB + TREVOGRUMAB
Activin A Antibody + GDF8 AntibodyMuscle-wasting diseasesREGN4461
REGN4461
LEPR AntibodyLipodystrophy and obesityREGN5069
REGN5069
GFRα3 AntibodyPain -
Phase 1 Trials
Cemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 AntibodyBasal cell carcinomaDUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyGrass allergy, peanut allergySARILUMAB* IL-6R Antibody
SARILUMAB*
IL-6R AntibodyPolyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritisEVINACUMAB 2
EVINACUMAB
ANGPTL-3 AntibodyRefractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemiaGARETOSMAB
GARETOSMAB
Activin A AntibodyFibrodysplasia Ossificans Progressiva (FOP)REGN3500
REGN3500*
IL-33 AntibodyAsthma, chronic obstructive pulmonary disease (COPD) -
Phase 1 Trials
AFLIBERCEPT^ VEGF-Trap
AFLIBERCEPT
VEGF-TrapNon-proliferative diabetic retinopathy (NPDR) without DMEALIROCUMAB* PCSK9 Antibody
ALIROCUMAB*
PCSK9 AntibodyHomozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatricsCemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 AntibodyNon-small cell lung cancer, cervical cancerDUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyAtopic dermatitis in pediatrics and adolescents, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitisSARILUMAB*
SARILUMAB*
IL-6R AntibodyPolymyalgia rheumaticaEVINACUMAB Angptl3 Antibody
EVINACUMAB
ANGPTL-3 AntibodyHomozygous familial hypercholesterolemia (HoFH)FASINUMAB† NGF Antibody
FASINUMAB†
NGF AntibodyChronic pain from osteoarthritis of the knee or hip
Trials Footnotes
* in collaboration with Sanofi
* in collaboration with Sanofi
† in collaboration with Teva and Mitsubishi Tanabe
† in collaboration with Teva and Mitsubishi Tanabe
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.